Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10195
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcDonald, Christine Fen
dc.contributor.authorZebaze, Roger M Den
dc.contributor.authorSeeman, Egoen
dc.date.accessioned2015-05-15T23:34:08Z
dc.date.available2015-05-15T23:34:08Z
dc.date.issued2006-07-11en
dc.identifier.citationOsteoporosis International : A Journal Established As Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of The Usa 2006; 17(10): 1546-51en
dc.identifier.govdoc16832714en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10195en
dc.description.abstractOral glucocorticoid therapy reduces bone mineral density (BMD) and increases fracture risk. It is uncertain whether inhaled glucocorticoids, the most commonly used long-term therapy for asthma, have a similar effect. If bone loss does occur, it is unclear whether this is preventable by calcitriol. Patients with asthma receiving inhalational plus intermittent oral glucocorticoids lose bone, and treatment with 0.5 microg/day of calcitriol will prevent bone loss.A 2-year randomized double-blind placebo-controlled trial. One hundred eight patients with asthma were stratified by gender, age, and inhaled glucocorticoid dose and treated with calcitriol (n=55) or placebo (n=53). There were 41 men (mean age 53.2+/-1.7 years) and 67 women (mean age 49.1+/-1 years) with moderate to severe asthma (requiring >/=800 microg/day of beclomethasone dipropionate or equivalent maintenance therapy). BMD values at the lumbar spine (LS) and femoral neck (FN) were measured at baseline and at 6, 12, and 24 months using dual x-ray absorptiometry.Changes in LS and FN BMD. Bone loss occurred in both groups at the FN (both p<0.03) and at the LS in the calcitriol (p<0.001), but not the control, group. Bone loss was not less in the calcitriol group at either site.Patients with asthma receiving inhalational plus intermittent short courses of oral glucocorticoids lose bone. Calcitriol is unlikely to be appropriate therapy against this bone loss.en
dc.language.isoenen
dc.subject.otherAdministration, Inhalationen
dc.subject.otherAsthma.drug therapyen
dc.subject.otherBone Density.drug effectsen
dc.subject.otherBone Density Conservation Agents.therapeutic useen
dc.subject.otherCalcitriol.therapeutic useen
dc.subject.otherDouble-Blind Methoden
dc.subject.otherFemaleen
dc.subject.otherFemur Neck.physiopathologyen
dc.subject.otherGlucocorticoids.adverse effects.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherOsteoporosis.chemically induced.physiopathology.prevention & controlen
dc.titleCalcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial.en
dc.typeJournal Articleen
dc.identifier.journaltitleOsteoporosis Internationalen
dc.identifier.affiliationchristine.mcdonald@austin.org.auen
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Austin Hospital, Heidelberg, Victoria, 3084, Australiaen
dc.identifier.doi10.1007/s00198-006-0158-2en
dc.description.pages1546-51en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/16832714en
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
16832714.pdf57 kBAdobe PDFView/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.